KCT0001052已完成未知
A randomized, open-label, multiple doses, crossover study to evaluate a pharmacokinetic drug interaction and safety of Candesartan free combination of Candesartan and Amlodipine and Candesartan monotherapy in healthy male volunteers
Chong Kun Dang0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 45(Year)（—）
- 性别
- Male
入选标准
- •Inclusion Criteria:
- •1.Healthy male volunteer is between 20 and 45 years of age(inclusive) at the pre-study(screening).
- •2.Volunteer who has 19kg/m² = BMI(Body Mass Index) = 26kg/m²
- •3.When volunteer in screening, Must include under the items.
- •a.100 mmHg = sitting SBP(systolic blood pressure) <140 mmHg
- •b.60 mmHg = sitting DBP(diastolic blood pressure) < 90 mmHg
- •c.45 bpm = Pulse < 95 bpm
- •4.Those who decided to join the clinical trials by themselves and to comply with the precautions written consent.
排除标准
- •Exclusion Criteria:
- •1.A previous history or present of clinically significant liver, renal, gastro-intestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric, hemato-oncological, cardiovascular disease.
- •2.Have a gastrointestinal disease history that can affect drug absorption(Crohn's disease, Ulcers, Gastro-esophageal reflux disease, Gastritis, etc.) or surgery (except simple appendectomy or hernia surgery).
- •3.The history of clinically significant hypersensitivity reaction about Investigational drugs and foods.
- •4.The history of drug abuse or drug abuse showed a positive for urine drug test.
- •5.Taking drugs have received any other investigational drug within 90 days prior to the first dosing and metabolizing enzyme inducers or inhibitors such as barbitals within 30 days prior to the first dosing.
- •6.Whole blood donation within 60 days prior to the first dosing or plasma donation within 30 days prior to the first dosing.
- •7.Taking drugs that clinical trials expected to affect within 14days or taking food containing caffeine, grapefruit within 7days before the first dosing.
- •8.A heavy alcohol consumer(alcohol>3cup/day or 3times/week within last 1month)
- •9.A heavy smoker(cigarette>10cigarettes/day)
- •10.The subject has positive results of serum tests(Hepatitis B, C, HIV(Human immunodeficiency virus) Test, Syphilis).
- •11.Have the Liver enzyme levels(AST:Aspartate Transaminase, ALT:Alanin Transaminase) or Bilirubin, total results greater than 1.5 times the UNL(Upper Normal Limit).
- •12.Have the result of Creatinine clearance under than 80mL/min(Cockcroft-Gault equation applicable).
- •13.The result of 12-lead ECG(electrocardiography) in screening test is QTc>450msec.
- •14.An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
研究者
相似试验
尚未招募
不适用
A randomized, open-label, multiple doses, crossover study to evaluate a pharmacokinetic drug interaction and safety of Amlodipine between free combination of Amlodipine and Candesartan and Amlodipine monotherapyKCT0001067Chong Kun Dang24
招募中
不适用
A randomized, open-label, multiple doses, crossover clinical study to compare the pharmacokinetic characteristics and the safety between administration of EL-1804 and co-administration of EL-1804R-1 and EL-1804R-2 in healthy adult subjectsKCT0006661Elyson Pharmaceutical40
已完成
不适用
Clinical study to evaluate pharmacokinetic drug-drug interaction and safety between nebivolol and rosuvastatiDiseases of the circulatory systemKCT0001794Elyson Pharmaceutical44
已完成
不适用
A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Rosuvastatin and Telmisartan in Healthy VolunteersKCT0000584Yuhan48
进行中（未招募）
Unknown
A randomized, open-label, multiple-dose, crossover study to compare the safety, pharmacokinetics and pharmacodynamics of DHNP-2001B to RD-02 in healthy adult subjectsKCT0008390DaehanNupharm44